PROGNYX

Home/The Watchtower/Epcoritamab plus R-CHOP cuts first-line DLBCL progression…

Editorial illustration for the Prognyx briefing on epcoritamab (Epkinly/Tepkinly) plus R-CHOP, CD20 x CD3 bispecific antibody

Briefing · From the Watchtower

Epcoritamab plus R-CHOP cuts first-line DLBCL progression risk 51% in Phase 3

Genmab and AbbVie's CD3xCD20 bispecific added to R-CHOP met the Phase 3 trial's primary endpoint in newly diagnosed DLBCL; in all enrolled patients (IPI 2-5, a key secondary endpoint) the risk of progression or death was cut 51% (HR 0.49, 95% CI 0.36-0.67, p<0.0001) versus R-CHOP alone, on a topline readout.

By · Founder, Prognyx ● Sourced to primary records Oncology
In brief: On 5 October 2026, Genmab and AbbVie reported that epcoritamab (Epkinly) added to R-CHOP met the primary endpoint of the Phase 3 EPCORE DLBCL-2 trial in newly diagnosed DLBCL. In all enrolled patients (IPI 2-5, a key secondary endpoint), the risk of disease progression or death was cut by 51% (HR 0.49, 95% CI 0.36-0.67, p<0.0001) versus R-CHOP alone; AbbVie calls it the first Phase 3 study of a bispecific-antibody combination to improve PFS in frontline DLBCL, moving the CD3xCD20 engager from its approved third-line-plus relapsed/refractory use toward the frontline.

What happened

Genmab and AbbVie said on 5 October 2026 that epcoritamab added to R-CHOP met the primary endpoint of the Phase 3 EPCORE DLBCL-2 trial in newly diagnosed DLBCL [1]. The trial record (NCT05578976) defines that primary endpoint as progression-free survival in patients with an International Prognostic Index of 3 to 5, with PFS in all enrolled patients (IPI 2 to 5) a key secondary endpoint [3]. In all enrolled patients (IPI 2 to 5), the companies reported the risk of disease progression or death was cut by 51% (HR 0.49, 95% CI 0.36-0.67, p<0.0001) against R-CHOP alone [1]. AbbVie describes the result as the first Phase 3 study of a bispecific-antibody combination to show a statistically significant PFS improvement in frontline DLBCL [2]. The announcement is topline: the registry record was last reviewed on 11 September 2026, lists the study as active but no longer recruiting, and carries no posted results, with primary completion set for June 2027 [3].

Why it matters

Epcoritamab is a CD3xCD20 T-cell engager approved in the US as Epkinly for relapsed or refractory DLBCL after two or more prior lines, under accelerated approval [4]. A frontline PFS win sharply expands the addressable population: newly diagnosed DLBCL is a far larger pool than third-line-plus relapsed disease, and the drug now has Phase 3 evidence to move into first-line combination with the R-CHOP backbone. The hazard ratio of 0.49 is the number BD teams will anchor on, though progression-free survival is not overall survival, and the companies have not released OS, response-rate or safety detail.

Who is exposed

Roche is the most direct read. Its CD20xCD3 bispecific Columvi (glofitamab) holds accelerated approval only in the same relapsed/refractory, post-second-line DLBCL setting [5]. If epcoritamab reaches the frontline ahead of Columvi, Roche's bispecific stays boxed into late lines while its competitor claims the larger, earlier patient pool. The provided sources contain no head-to-head or cross-trial comparison with Roche's Polivy (polatuzumab vedotin) or its frontline POLARIX data, so Prognyx cannot quantify the frontline threat to that specific regimen from public information here.

This also compounds Genmab's own momentum. On 29 June 2026 the company reported that epcoritamab plus lenalidomide cut progression or death by 60% (US censoring, HR 0.40) and 56% (ex-US, HR 0.44) versus R-GemOx in relapsed/refractory DLBCL in the separate EPCORE DLBCL-4 trial [6]. Two readouts in four months, in different lines, signal a drug being pushed across the full DLBCL treatment arc.

What to watch next

  • Full EPCORE DLBCL-2 data: the companies say results will go to a future medical meeting, with no date given [1].
  • Regulatory engagement: the release states Genmab and AbbVie will engage global regulatory authorities, without a filing date or agency [1].
  • EPCORE DLBCL-2 primary completion: June 2027 [3].
  • A newer Phase 2 of epcoritamab plus R-CHOP in aggressive non-Hodgkin lymphoma (NCT07588698) is set to open on 15 November 2026 [7].

The now-what

For a competitor running a frontline DLBCL asset, three moves are on the table. Pressure-test your differentiation on safety and administration: epcoritamab is a T-cell engager and the dossier carries no safety readout for this trial, so the tolerability comparison is unresolved. Wait for the OS and complete-response data at the medical-meeting presentation before repricing your program; a PFS-only topline is a weak basis for a strategy pivot. And if you are weighing a CD20xCD3 or frontline DLBCL partnership, the negotiating clock moves up now that frontline Phase 3 proof exists.

What Prognyx could not verify

Prognyx could not confirm any comparison of EPCORE DLBCL-2 with Roche's Polivy or its POLARIX data from public information. OS, response and safety data are pending. No BLA or sBLA filing date for the frontline indication is available. The registry record has not been updated since the readout.

Verdict: elevated threat to relapsed/refractory-only bispecific positioning, with the real window opening at full data and first regulatory filing, neither yet dated.

Questions this briefing answers

How much did epcoritamab plus R-CHOP reduce progression or death in EPCORE DLBCL-2?

By 51% in all enrolled patients (IPI 2 to 5, a key secondary endpoint) versus R-CHOP alone (HR 0.49, 95% CI 0.36-0.67, p<0.0001), per the 5 October 2026 topline announcement [1]. Per the trial registry, the primary endpoint is PFS in patients with an IPI of 3 to 5, with PFS in all enrolled patients (IPI 2 to 5) the key secondary endpoint [3].

Is epcoritamab approved for first-line DLBCL now?

No. Epkinly's current US approval covers relapsed or refractory DLBCL after two or more prior lines under accelerated approval [4]; the frontline result is a topline Phase 3 readout, and Genmab and AbbVie say they will engage regulators but have given no filing date [1].

Sources: every claim traces to the primary record

  1. Genmab newsroom, EPCORE DLBCL-2 topline release
  2. AbbVie newsroom, EPCORE DLBCL-2 release
  3. ClinicalTrials.gov NCT05578976
  4. FDA label (DailyMed), EPKINLY (epcoritamab)
  5. FDA label (DailyMed), COLUMVI (glofitamab)
  6. SEC 6-K, Genmab EPCORE DLBCL-4 readout
  7. ClinicalTrials.gov NCT07588698

How this briefing was produced: Drafted and audited by the Prognyx engine against the primary sources cited above, then published automatically for clearing the audit threshold set by Rali Filali. Below that threshold, a briefing is not published. The full method.

Want this on your pipeline?
Get a free sample competitive brief on one of your assets, sourced, sharp, no strings.
Request a sample brief → Or read how Prognyx runs continuous oncology competitive intelligence.

Prognyx briefings are built from public information and reflect Prognyx's analysis. They are not investment advice and do not promote any product or off-label use.